Menu
← Oncology Approval Tracker
FDA DECISION ·
Avmapki Fakzynja Co-pack
avutometinib + defactinib · Verastem
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
For adults with recurrent low-grade serous ovarian cancer harboring a KRAS mutation after prior systemic therapy.
LAMPGEN ANALYSIS
Why it matters
Dual RAF/MEK and FAK pathway inhibition created a targeted option in a rare ovarian cancer subtype; clinical benefit requires confirmation.
What research teams should watch
Verify low-grade serous histology and KRAS status, then explain the distinct schedules of the two oral agents.
PRIMARY RECORDS